ClinicalTrials.gg
Drug

Talquetamab clinical trials

Also written JNJ-64407564 and Talvey.

studies test it
32
open now
21
in phase 3
7
first study started
2017

How each study uses talquetamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the talquetamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
9 Aug 2023 · TALVEY · BLA 761342 (FDA, Drugs@FDA)
European Union
21 Aug 2023 · Talvey · EMEA/H/C/005864 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Talquetamab
31
Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564
3
GPRC5D x CD3 Bispecific Antibody JNJ-64407564
2
GPRC5D x CD3 DuoBody Antibody JNJ-64407564
2
GPRC5D/CD3 DuoBody Antibody JNJ-64407564
2

Brand

Talvey
3

Development codes

JNJ-64407564
15

Studies by the year they started

31 studies that test it; most in 2025 (7); 1 more planned to start later

Studies that test talquetamab, by start year
YearStudies
20171
20201
20212
20225
20234
20245
20257
20266

By phase

A phase 1/2 study counts in both.

Phase 1
9
Phase 2
18
Phase 3
7
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 20

Janssen Research & Development, LLC (11) · PETHEMA Foundation (1) · Janssen Pharmaceutical K.K. (1) · Alliance for Clinical Trials in Oncology (1) · University of Arkansas (1) · Polish Myeloma Consortium (1) · Montefiore Medical Center (1) · First Affiliated Hospital of Chongqing Medical University (1)

Often tested with

Tested in the same studies.

Teclistamab (14) · Lenalidomide (4) · Dexamethasone (3) · Pomalidomide (2) · Ciltacabtagene autoleucel (2) · Daratumumab (2) · Bortezomib (2) · Ramantamig (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 11, 1 in phase 3

Studies that test talquetamab, phase 3 first.

Studies

Open first, then newest update. How each study uses talquetamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test talquetamab →

Given beside what is tested · 6 — talquetamab is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call talquetamab · ClinicalTrials.gg INT002094

  • MeSH (NLM) C000730985talquetamabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 4W3KFI3TN3TALQUETAMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q116777032talquetamabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C171840TalquetamabOne source FDA
  • DrugBank DB16678One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.